The new treatments for hepatitis C virus: An advanced practice provider's perspective
Lisa Cervantes – 20 January 2015 – Watch a video presentation of this article
Lisa Cervantes – 20 January 2015 – Watch a video presentation of this article
Sumit Singla, Cyrus Piraka – 20 January 2015 – Watch a video presentation of this article
Peter Bannas, Diego Hernando, Utaroh Motosugi, Alejandro Roldan, Scott Brian Reeder – 20 January 2015 – Watch a video presentation of this article
Peter Bannas, Diego Hernando, Utaroh Motosugi, Alejandro Roldan, Scott Brian Reeder – 20 January 2015 – Watch a video presentation of this article
Jayant A. Talwalkar – 20 January 2015 – Watch a video presentation of this article
Fasiha Kanwal – 20 January 2015 – Watch a video presentation of this article
Raoul Poupon – 20 January 2015 – Several lines of evidence show that serum alkaline phosphatase (AP) is not only a signpost of cholestasis but also a surrogate marker of the severity of primary biliary cirrhosis and primary sclerosing cholangitis. In the present opinion article, we review and discuss the putative role of liver AP in health and in cholestatic diseases.
Jean‐François Dufour – 20 January 2015
20 January 2015
Jennifer C. Price, Norah A. Terrault – 20 January 2015 – Although chronic infection with hepatitis C virus (HCV) is the leading indication for liver transplantation in the United States, graft and patient survival rates are reduced because of HCV recurrence after transplant. Interferon‐based antiviral treatment administered either before or after transplant to prevent or treat HCV recurrence, respectively, is limited because of poor tolerability and low efficacy.